Attenuated culture of high-pathogenic porcine reproductive and respiratory syndrome virus attenuated vaccine GDr strain

• Main Authors: NING YIBAO, HAN MINGYUAN, ZHANG ZHIGANG, LI JIAAI, ZHANG LEI, CHEN JIAN, LAI YUEHUI, ZHENG JIE, LUO JUN, SHEN QINGCHUN, LIU YEBING
• Format: Patent
• Language: Chinese; English
• Published: 04.01.2012
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS THEREOF; CULTURE MEDIA; ENZYMOLOGY; HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; METALLURGY; MICROBIOLOGY; MICROORGANISMS OR ENZYMES; MUTATION OR GENETIC ENGINEERING; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; PROCESSES USING MICROORGANISMS; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS; SPIRITS; VINEGAR; WINE

The invention relates to attenuated culture of a high-pathogenic porcine reproductive and respiratory syndrome virus attenuated vaccine GDr strain. In the attenuated culture, a high-pathogenic porcine reproductive and respiratory syndrome wild strain separated in China is identified comprehensively and is subjected to continuous passage in Marc145 cells, so that the virulence of the wild strain is attenuated to obtain attenuated vaccine GDr strain virus (the collection number is CGMCC No.3599), and is subjected to back passage until the porcine virulence is non-return and the hereditary performance is stable. The strain can be proliferated efficiently in the Marc145 cells, is low in virulence and has the high immunogenicity, the minimum immunizing dose can reach 104 tissue culture infective dose (TCID50), and the immune duration of inoculated pigs can reach 4 months.